Cost-utility of VIRTUAL FIBROWALK

Sponsor
Hospital Universitari Vall d'Hebron Research Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05091697
Collaborator
Universitat Autonoma de Barcelona (Other)
142
1
2
8.1
17.4

Study Details

Study Description

Brief Summary

The main objective of this study is to assess the effectiveness and cost-utility of the VIRTUAL FIBROWALK multicomponent treatment program as coadjuvant of treatment-as- usual (TAU) compared to TAU alone.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Multicomponent treatment VIRTUAL FIBROWALK + TAU
N/A

Detailed Description

This is a two-arm RCT focused on the effectiveness and cost-utility of the multicomponent program VIRTUAL FIBROWALK as coadjuvant of treatment-as- usual (TAU) vs. TAU alone (in a 3-month follow-up RCT) VIRTUAL FIBROWALK combines multicomponent approach based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness training.

Study Design

Study Type:
Interventional
Actual Enrollment :
142 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Cost-utility of the Multicomponent Program VIRTUAL FIBROWALK in Patients With Fibromyalgia
Actual Study Start Date :
Apr 26, 2021
Anticipated Primary Completion Date :
Dec 10, 2021
Anticipated Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Multicomponent treatment VIRTUAL FIBROWALK + TAU

VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training

Behavioral: Multicomponent treatment VIRTUAL FIBROWALK + TAU
To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)

Active Comparator: Treatment as Usual (TAU)

Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient

Behavioral: Multicomponent treatment VIRTUAL FIBROWALK + TAU
To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)

Outcome Measures

Primary Outcome Measures

  1. Revised Fibromyalgia Impact Questionnaire (FIQR) [Change from baseline values at 6 months]

    The FIQR comprises three dimensions: physical dysfunction (scores from 0 to 30), overall impact (scores from 0 to 20), and intensity of the symptoms (scores from 0 to 50) is used to measure the impact generated by FM during the last week. It consists of 21 items, which are answered on a numerical rating scale of 11 points (from 0 to 10). Total scores can range from 0 to 100, with higher scores reflecting greater deterioration.

  2. Client Service Receipt Inventory (CSRI) [Change from baseline values at 6 months]

    The Client Service Receipt Inventory (CSRI) is a tool used to collect information on the whole range of services and supports study participants may use. This data can be used for a wide range of applications, including estimating the costs of service receipt.

  3. EuroQoL questionnaire (EQ-5D-5L) [Change from baseline values at 6 months]

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

Secondary Outcome Measures

  1. Tampa Scale for Kinesiophobia (TSK-11) [Change from baseline values at 6 months]

    TSK-11 is used to assess fear of pain and movement. It consists of 11 items, which are answered on a Likert scale of 4 points. Total scores of each scale range from 11 to 44, where higher scores indicate a greater fear of pain and movement.

  2. Hospital Anxiety and Depression Scale (HADS) [Change from baseline values at 6 months]

    HADS is used to quantify the severity of anxiety and depression symptoms. It consists of two dimensions (anxiety and depression) of 7 items each responding on a Likert scale of 4 points. Total scores of each scale (HADS-A and HADSD) range from 0 to 21, where higher scores indicate greater severity of symptoms.

  3. Physical Function of the 36-Item Short Form Survey (SF-36) [Change from baseline values at 6 months]

    Physical Function of the 36-Item Short Form Survey (SF-36) was used to measure physical function.This dimension comprises a total of 10 items, which are answered on a Likert scale of 3 points. Total scores on each scale are then transformed and can range from 0 to 100, with higher scores indicate better physical function.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults from 18 to 75 years-old.

  • 1990 American College of Rheumatology (ACR) classification criteria + the 2011 modified ACR diagnostic criteria for fibromyalgia

  • Able to understand Spanish and accept to participate in the study.

Exclusion Criteria:
  • Participating in concurrent or past RCTs (previous year).

  • Comorbidity with severe mental disorders (i.e. psychosis) or neurodegenerative diseases (i.e. Alzheimer) that that would limit the ability of the patient to participate in the RCT.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayte Serrat Barcelona Spain 08035

Sponsors and Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute
  • Universitat Autonoma de Barcelona

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier:
NCT05091697
Other Study ID Numbers:
  • COST-UTILITY VIIRTUAL FW
First Posted:
Oct 25, 2021
Last Update Posted:
Dec 9, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospital Universitari Vall d'Hebron Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 9, 2021